About

Dr. Shenhong Wu is a Medical Oncologist and Clinical Associate Professor of Medicine at Stony Brook University. His primary focus is on clinical care and research for patients with cancers of the prostate, bladder, kidney, and testis. His work includes characterizing and managing dermatologic adverse events related to agents targeting the PD-1 receptor, as well as investigating the incidence, risk, and management of various adverse effects associated with targeted cancer therapies, including multikinase inhibitors, mTOR inhibitors, and other molecularly targeted agents. Dr. Wu has contributed to understanding the dermatologic toxicities, such as skin rashes, nail changes, xerosis, and alopecia, and has published extensively on the safety profiles of these treatments. His research aims to improve the management of side effects in cancer patients receiving targeted therapies, thereby enhancing treatment tolerability and patient quality of life.

Research topics

• Internal medicine
• Medicine
• Oncology
• Dermatology

Selected publications

• Abstract 5746: The risk of high-grade hyperglycemia with PI3K inhibitors-a meta-analysis

  Cancer Research · 2026-04-03

  articleSenior author

  Abstract Background: Phosphoinositide 3-kinase (PI3K) inhibitors are a promising therapeutic class in cancer treatment and their clinical utility has been limited by toxicity, particularly high-grade hyperglycemia. Currently the overall risk of hyperglycemia in patients treated with PI3K inhibitors has not been well understood. We performed a meta-analysis on the risk of high-grade hyperglycemia in patients treated with PI3K inhibitors based on currently available published randomized control trial (RCT) data. Methods: A systematic meta-analysis was conducted including phase II-III RCTs evaluating PI3K inhibitors in cancer patients. The primary endpoints were the incidence and relative risk of grade ≥3 hyperglycemia. Pooled effect sizes were calculated using random- or fixed-effects models based on the heterogeneity of included studies. Results: A total of 4977 patients across 16 eligible RCTs were included for analysis. The overall incidence of high-grade hyperglycemia was 12.7% (637/4977). Compared to controls, PI3K inhibition was associated with a significantly increased risk of high-grade hyperglycemia (RR: 2.27; 95% CI, 1.74-2.80; p < 0.001), with moderate heterogeneity (I2 = 38.9%). Subgroup analyses revealed that control type significantly moderated toxicity risk (p < 0.001), with the greatest risk observed in trials with placebo controls (RR: 2.60; 95% CI, 2.05-3.15) and active controls (RR:1.50; 95% CI, 0.49-2.52). PI3K inhibitor subtype also moderated risk (p < 0.001). PI3K-α selective inhibitors were associated with the highest risk (RR: 3.80; 95% CI, 2.50-5.11), followed by pan-PI3K (RR: 2.15; 95% CI, 1.79-2.52) and PI3K/mTOR dual inhibitors (RR:1.46; 95% CI, 0.61-2.31). Class I α/β/δ inhibitors showed no significant elevation. Conclusions: PI3K inhibitors substantially increased the risk of grade ≥3 hyperglycemia, with heterogeneity driven by control type and inhibitor subtype. The markedly elevated risk with PI3K-α selective agents highlights the need for vigilant metabolic monitoring and tailored management strategies in clinical use. Citation Format: Zhan Rong, Shenhong Wu. The risk of high-grade hyperglycemia with PI3K inhibitors-a meta-analysis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5746.

  PublisherDOI

• Understanding the Impact of Risk Tolerance in Open-Offer Kidney Acceptance

  American Journal of Transplantation · 2025-08-01

  article
  PublisherDOI

• Increased Risk of Hyperglycemia in Advanced Urothelial Cancer Patients Treated with Enfortumab Vedotin: A Systematic Review and Meta-Analysis

  Cancer Investigation · 2025-05-13 · 4 citations

  reviewSenior authorCorresponding

  BACKGROUND: Enfortumab vedotin, an anti-nectin-4 antibody-drug conjugate, is a key treatment for advanced urothelial cancer. However, hyperglycemia, a major adverse event, varies in incidence and can progress to diabetic ketoacidosis. We conducted a systematic review and meta-analysis to quantify the risk of hyperglycemia with enfortumab vedotin. MATERIAL AND METHODS: We searched studies published through September 30, 2024. Eligible clinical trials evaluated enfortumab vedotin as a monotherapy or combined with pembrolizumab. Pooled incidence and relative risk of hyperglycemia were calculated using random- or fixed-effects models. RESULTS: < 0.001). CONCLUSION: Enfortumab vedotin is associated with a significantly increased risk of all-grade and high-grade hyperglycemia in urothelial cancer. Its combination with pembrolizumab does not appear to elevate this risk further. Routine glucose monitoring and early intervention should be implemented, particularly in high-risk patients.

  PublisherDOI

• Increased risk of hyperglycemia in patients with advanced urothelial cancer treated with enfortumab vedotin: A systematic review and meta-analysis.

  Journal of Clinical Oncology · 2024-06-01 · 1 citations

  reviewSenior author

  e15001 Background: Enfortumab vedotin (EV), an antibody-drug conjugate targeting anti-nectin-4, which is highly expressed in urothelial cancers, has emerged as an effective therapy in the management of previously treated advanced urothelial cancer. urothelial cancer. Severe hyperglycemia has been recognized as an unexpectedly adverse effect, and can lead to discontinuation of EV or fatal event. To assess the overall risk of hyperglycemia associated with the use of EV, a systematic review and meta-analysis of published clinical trials was performed. Methods: A comprehensive review through 2023 of PubMed and American Society of Clinical Oncology conferences was performed to identify relevant clinical trials and abstracts. Eligible studies were clinical trials of patients with urothelial cancer receiving EV at the standard dose with data on hyperglycemia available. Incidence rates, relative risks, and 95% confidence intervals were calculated using random-effects or fixed-effects models. Results: Our search culminated in the inclusion of 1,150 patients from four trials, with 859 of them receiving EV. The summary incidences for all-grade and high-grade hyperglycemia were 9.9% (95% CI: 7.8-12.5%) and 6.0% (95% CI: 4.6-7.8%) respectively. Patients treated with EV had an increased risk of developing hyperglycemia in comparison with chemotherapy with an RR of 19.66 (95% CI: 2.66-145.55, P=0.004) for all-grade and 26.54 (95% CI: 1.59-444.48, P=0.023). In comparison with single-agent EV, its combination with pembrolizumab did not significantly increase the risk of all-grade hyperglycemia (P=0.148). Conclusions: EV is associated with a significantly increased risk of all-grade and high-grade hyperglycemia.

  PublisherDOI

• Incidence and risk of peripheral sensory neuropathy with enfortumab vedotin in patients with advanced urothelial cancer: A systematic review and meta-analysis.

  Journal of Clinical Oncology · 2023-06-01 · 4 citations

  reviewSenior author

  e16556 Background: Enfortumab Vedotin (EV), a first-in-class antibody-drug conjugate directed against Nectin-4, is associated with peripheral sensory neuropathy (SN) in the treatment of advanced urothelial cancers. A systematic literature review and meta-analysis were conducted to assess the overall incidence and risk of SN in patients receiving EV. Methods: A systematic search through mid-2022 of PubMed, Cochrane Library, and recent ASCO annual and genitourinary meetings was conducted to identify relevant studies. Eligible studies were clinical trials of patients with urothelial cancer receiving single-drug EV at the standard dose with data on SN available. Incidence and relative risk (RR) of SN were calculated using both a fixed-effects and a random-effects model. Results: Of the 93 initial publications identified, there were 5 trials that met the eligibility criteria and included a total 996 patients with 630 patients receiving EV at the standard dose. The summary incidence of all-grade SN was 42.3% (95% CI: 38.5-46.2%) with the incidence of high-grade SN being 3.1% (95% CI: 1.9-4.9%). In comparison with standard chemotherapy, there was no significant difference for EV in all-grade SN (RR = 0.95, 95% CI: 0.77-1.18, p = 0.66) and high-grade SN (RR = 1.69, 95% CI: 0.40-7.21, p = 0.48). In some cases, SN also led to discontinuation of EV (4.4%, 95% CI: 2.1-6.7%). Conclusions: EV is associated with a substantial toxicity of peripheral sensory neuropathy, and its risk may be comparable to that of standard chemotherapy. Further studies are needed to assess and reduce the risk of severe neuropathy.

  PublisherDOI

• The Utility of 24-h Ambulatory Blood Pressure Monitoring for the Diagnosis and Management of White Coat Hypertension in a Primary Care Setting

  Journal of Primary Care & Community Health · 2022-01-01 · 3 citations

  articleOpen accessSenior author

  Objectives: Twenty-four-hour ambulatory blood pressure monitoring (ABPM) is recommended in patients with white coat hypertension (HTN) by national guideline, but was poorly utilized, and is available only in very limited subspecialty clinics. We aim to examine the feasibility and utility of ABPM in a primary care setting in the diagnosis and management of white coat HTN including the implementation and modification of antihypertensive therapy. Methods: Patients who have elevated blood pressure in clinic office but normal blood pressure readings at home are eligible for 24-h ambulatory BP monitoring. We analyzed data from patients who were suspected to have white coat HTN in the last 2 years underwent ABPM in our practice. Results: Among 68 patients, 54 patients met the selection criteria. ABPM showed that 13 patients had normal BP (24%), while 41 patients (76%) had persistent HTN. Among these patients with persistent HTN, 28 patients had intervention including 24 patients prescribed with new anti-hypertensive medication or medication increase, 3 patients prescribed with additional lifestyle modification and one started CPAP.13 patients with slightly elevated BP (133/77 for average daytime BP) didn’t have medication adjustment. Conclusion: ABPM has substantial utility in the diagnosis and management of white coat HTN in a primary care setting.

  PublisherDOI

• Risks and management of hypertension in cancer patients undergoing targeted therapy: a review

  Clinical Hypertension · 2022-01-01 · 16 citations

  reviewOpen accessSenior authorCorresponding

  BACKGROUND: Rapid progress over the last decade has added numerous agents targeting specific cellular signaling pathways to the treatment armamentarium for advanced cancer. However, many of these agents can cause hypertension resulting in major adverse cardiovascular event. METHODS AND RESULTS: A systematic literature search was performed on the databases PubMed and Google Scholar for papers published in English until December 2020. This review summarizes the risk, mechanism, diagnosis, and management of hypertension in cancer patients undergoing targeted therapy. The risk and pathogenesis of hypertension vary widely with different classes of targeted agents. Currently there is a paucity of data investigating optimal management of hypertension with targeted therapy. A practical approach is discussed with a focus on the goal of blood pressure control as well as drug selection based on the mechanism of hypertension in the context of advanced cancer, treatment toxicity, comorbidity, and drug-drug interactions. This review also discusses many studies that have explored hypertension as a biomarker for cancer treatment efficacy and as a pharmacodynamic biomarker to titrate drug dose. CONCLUSIONS: The diversity of targeted agents has provided important insights into the pathogenesis of hypertension in cancer patients. The underlying mechanism may provide a guidance to the management of hypertension. Further studies are needed to investigate optimal treatment and hypertension as a biomarker for cancer treatment.

  PublisherOA PDFDOI

• Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis

  Critical Reviews in Oncology/Hematology · 2022 · 17 citations

  • Medicine
  • Internal medicine
  • Dermatology
  PublisherDOI

• Improving tolerability of pembrolizumab with weight based dosing: A meta-analysis.

  Journal of Clinical Oncology · 2021-05-20 · 1 citations

  articleSenior author

  2639 Background: Pembrolizumab, a PD-1 immune checkpoint inhibitor (ICI), has demonstrated significant clinical activity in various cancers. Despite a favorable toxicity profile, discontinuation due to adverse events including immune related adverse events (irAE) has been reported. We conducted a meta-analysis of published clinical trials to evaluate the tolerability of pembrolizumab in cancer patients. Methods: A systematic review was conducted of relevant studies from the databases of PubMed and abstracts presented at American Society of Clinical Oncology (ASCO) from June 2015 until September 2020. Eligible studies included prospective clinical trials that reported a discontinuation rate due to adverse effects. Incidence, relative risk and 95% confidence intervals (CI) were calculated by employing fixed or random effects models. Results: A total of 6,380 patients with a variety of hematologic and solid malignancies from 20 studies of pembrolizumab were included for analysis. The overall rate of pembrolizumab discontinuation due to adverse events was 8.2% (95% CI: 6.4-10.4%). The discontinuation rate of pembrolizumab was not significantly lower than the chemotherapy controls, with RR of 0.84 (95% CI: 0.58-1.12, p = 0.33). However, the discontinuation rate of pembrolizumab was significantly higher compared to placebo control with RR of 2.20 (95% CI: 1.36-3.54, p &lt; 0.001), and significantly lower compared to ipilimumab with RR of 0.58 (95% CI: 0.34-0.99, p = 0.04) respectively. The discontinuation rate varied widely among different tumor types with the lowest rate of 0.8% (95% CI: 0.2-3%) in gastric cancer, and the highest of 13.5% (95% CI: 10.8-16.8%) in head and neck squamous cell carcinoma. Interestingly, the discontinuation rate varied with pembrolizumab dosing, with the fixed dosing of 200mg being 9.2% (95% CI: 6.9-12%) and the weight-based dosing being 6.5% (95% CI: 4.8-8.8%). The weight-based dosing was associated with a significantly lower discontinuation rate compared to controls with RR of 0.62 (95% CI: 0.47-0.81, p &lt; 0.0001), while the fixed dosing had similar discontinuation rate with RR of 1.03 (95% CI: 0.89-1.20, p = 0.67). Conclusions: The tolerability of pembrolizumab may be comparable to chemotherapy in cancer patients and may vary with its dosing. Future studies are warranted to evaluate the impact of different dosing.

  PublisherDOI

• Tolerability of axitinib in advanced renal cell carcinoma: A meta-analysis.

  Journal of Clinical Oncology · 2021-05-20 · 2 citations

  articleSenior author

  e16536 Background: Axitinib has been used extensively as a single agent or in combination with immunotherapy in the treatment of advanced renal cell carcinoma. It can be often discontinued due to adverse events. A meta-analysis of clinical trials was performed to evaluate the overall tolerability of axitinib in this setting. Methods: PubMed (Up to November 2020) was searched to identify clinical trials of axitinib in advanced or metastatic renal cell carcinoma. Reported data was collected to include axitinib and control discontinuation due to adverse events. A random or fixed effects model was used to determine summary incidences, relative risks, and 95% confidence intervals depending on the heterogeneity of included studies. Results: A total of 11 studies including 4,056 patients (axitinib alone n = 1384, axitinib combination n = 987, control n = 1685) were included for analysis. The summary discontinuation rate for axitinib due to adverse events was 13.4% (95% CI; 11.7-15.2%) with 8.9% (95% CI: 5.3-14.6%) as a single agent and 26.6% (95% CI:17.8 –37.8%) in combination with other agents. In comparison with controls based on randomized controlled studies, axitinib overall has similar discontinuation rate due to adverse events (RR: 1.18, 95% CI: 0.77-1.80). However, there was a significantly higher discontinuation rate with axitinib in combination with other agents including immunotherapeutic agents PD-L1 inhibitors than control treatment (RR: 1.52, 95% CI: 1.24-1.86). Conclusions: The tolerability of axitinib may vary significantly with its use as a single agent or in combination in the treatment of advanced renal cell carcinoma. Further studies are needed to improve its tolerability as a part of combination therapy.

  PublisherDOI

Frequent coauthors

• Mario E. Lacouture

  Memorial Sloan Kettering Cancer Center

  91 shared

• Raji Shameem

  Fox Chase Cancer Center

  61 shared

• Muhammad Saad Hamid

  St. Jude Children's Research Hospital

  53 shared

• Kevin Y. Xu

  Washington University in St. Louis

  50 shared

• Xiaolei Zhu

  39 shared

• William L. Dahut

  National Institutes of Health

  27 shared

• Xiao Su

  21 shared

• Yuxia Jia

  20 shared

Education

• phD

  Medical College of Wisconsin

  1996

• md

  Wenzhou Medical University

  1987